Urine vascular biomarkers in Sturge-Weber syndrome

Aditya K. Sreenivasan, Catherine D. Bachur, Kira E. Lanier, Adam S. Curatolo, Susan M. Connors, Marsha A. Moses, Anne Marie Spalding Comi

Research output: Contribution to journalArticle

Abstract

Sturge-Weber syndrome (SWS) consists of a capillary-venous vascular malformation of the brain, skin and eye. Urine vascular biomarkers have been demonstrated to be abnormal in other vascular anomalies and to correlate with clinical severity and progression. The current study investigated the use of urinary matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) levels to non-invasively monitor the progression of SWS. Fifty-four urine samples were collected from patients seen at the Hunter Nelson Sturge-Weber Center at Kennedy Krieger Institute. Urine was analyzed for MMP-2, MMP-9, VEGF and bFGF levels and correlated with clinical outcome at the time of urine collection (n = 48) and 1 year following urine collection (n = 22). Analysis revealed that MMP-2 (p = 0.033) and MMP-9 (p = 0.010) were significantly more likely to be present in the urine of SWS subjects compared to controls and that bFGF was significantly more likely to be present at abnormal levels (p = 0.005). MMP-2 correlated with a more severe clinical score at the time of urine collection, while both MMP-2 and MMP-9 levels correlated with greater disease severity at time of collection. bFGF levels correlated with improved clinical score 1 year after urine collection. These results suggest that MMP-2 and MMP-9 levels may be useful in assessing SWS progression, as well as indicating which patients might benefit from more aggressive treatment, while bFGF levels may be useful in judging the efficacy of neurologic treatment in SWS.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
JournalVascular Medicine
Volume18
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Sturge-Weber Syndrome
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Fibroblast Growth Factor 2
Blood Vessels
Urine Specimen Collection
Biomarkers
Urine
Vascular Endothelial Growth Factor A
Central Nervous System Vascular Malformations
Nervous System
Skin

Keywords

  • angiogenesis
  • biological markers
  • fibroblast growth factor
  • remodeling
  • risk assessment
  • vascular endothelial growth factor-A

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sreenivasan, A. K., Bachur, C. D., Lanier, K. E., Curatolo, A. S., Connors, S. M., Moses, M. A., & Comi, A. M. S. (2013). Urine vascular biomarkers in Sturge-Weber syndrome. Vascular Medicine, 18(3), 122-128. https://doi.org/10.1177/1358863X13486312

Urine vascular biomarkers in Sturge-Weber syndrome. / Sreenivasan, Aditya K.; Bachur, Catherine D.; Lanier, Kira E.; Curatolo, Adam S.; Connors, Susan M.; Moses, Marsha A.; Comi, Anne Marie Spalding.

In: Vascular Medicine, Vol. 18, No. 3, 06.2013, p. 122-128.

Research output: Contribution to journalArticle

Sreenivasan, AK, Bachur, CD, Lanier, KE, Curatolo, AS, Connors, SM, Moses, MA & Comi, AMS 2013, 'Urine vascular biomarkers in Sturge-Weber syndrome', Vascular Medicine, vol. 18, no. 3, pp. 122-128. https://doi.org/10.1177/1358863X13486312
Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA et al. Urine vascular biomarkers in Sturge-Weber syndrome. Vascular Medicine. 2013 Jun;18(3):122-128. https://doi.org/10.1177/1358863X13486312
Sreenivasan, Aditya K. ; Bachur, Catherine D. ; Lanier, Kira E. ; Curatolo, Adam S. ; Connors, Susan M. ; Moses, Marsha A. ; Comi, Anne Marie Spalding. / Urine vascular biomarkers in Sturge-Weber syndrome. In: Vascular Medicine. 2013 ; Vol. 18, No. 3. pp. 122-128.
@article{8378cc98957b4c6bbf65177d59d22f96,
title = "Urine vascular biomarkers in Sturge-Weber syndrome",
abstract = "Sturge-Weber syndrome (SWS) consists of a capillary-venous vascular malformation of the brain, skin and eye. Urine vascular biomarkers have been demonstrated to be abnormal in other vascular anomalies and to correlate with clinical severity and progression. The current study investigated the use of urinary matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) levels to non-invasively monitor the progression of SWS. Fifty-four urine samples were collected from patients seen at the Hunter Nelson Sturge-Weber Center at Kennedy Krieger Institute. Urine was analyzed for MMP-2, MMP-9, VEGF and bFGF levels and correlated with clinical outcome at the time of urine collection (n = 48) and 1 year following urine collection (n = 22). Analysis revealed that MMP-2 (p = 0.033) and MMP-9 (p = 0.010) were significantly more likely to be present in the urine of SWS subjects compared to controls and that bFGF was significantly more likely to be present at abnormal levels (p = 0.005). MMP-2 correlated with a more severe clinical score at the time of urine collection, while both MMP-2 and MMP-9 levels correlated with greater disease severity at time of collection. bFGF levels correlated with improved clinical score 1 year after urine collection. These results suggest that MMP-2 and MMP-9 levels may be useful in assessing SWS progression, as well as indicating which patients might benefit from more aggressive treatment, while bFGF levels may be useful in judging the efficacy of neurologic treatment in SWS.",
keywords = "angiogenesis, biological markers, fibroblast growth factor, remodeling, risk assessment, vascular endothelial growth factor-A",
author = "Sreenivasan, {Aditya K.} and Bachur, {Catherine D.} and Lanier, {Kira E.} and Curatolo, {Adam S.} and Connors, {Susan M.} and Moses, {Marsha A.} and Comi, {Anne Marie Spalding}",
year = "2013",
month = "6",
doi = "10.1177/1358863X13486312",
language = "English (US)",
volume = "18",
pages = "122--128",
journal = "Vascular Medicine",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Urine vascular biomarkers in Sturge-Weber syndrome

AU - Sreenivasan, Aditya K.

AU - Bachur, Catherine D.

AU - Lanier, Kira E.

AU - Curatolo, Adam S.

AU - Connors, Susan M.

AU - Moses, Marsha A.

AU - Comi, Anne Marie Spalding

PY - 2013/6

Y1 - 2013/6

N2 - Sturge-Weber syndrome (SWS) consists of a capillary-venous vascular malformation of the brain, skin and eye. Urine vascular biomarkers have been demonstrated to be abnormal in other vascular anomalies and to correlate with clinical severity and progression. The current study investigated the use of urinary matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) levels to non-invasively monitor the progression of SWS. Fifty-four urine samples were collected from patients seen at the Hunter Nelson Sturge-Weber Center at Kennedy Krieger Institute. Urine was analyzed for MMP-2, MMP-9, VEGF and bFGF levels and correlated with clinical outcome at the time of urine collection (n = 48) and 1 year following urine collection (n = 22). Analysis revealed that MMP-2 (p = 0.033) and MMP-9 (p = 0.010) were significantly more likely to be present in the urine of SWS subjects compared to controls and that bFGF was significantly more likely to be present at abnormal levels (p = 0.005). MMP-2 correlated with a more severe clinical score at the time of urine collection, while both MMP-2 and MMP-9 levels correlated with greater disease severity at time of collection. bFGF levels correlated with improved clinical score 1 year after urine collection. These results suggest that MMP-2 and MMP-9 levels may be useful in assessing SWS progression, as well as indicating which patients might benefit from more aggressive treatment, while bFGF levels may be useful in judging the efficacy of neurologic treatment in SWS.

AB - Sturge-Weber syndrome (SWS) consists of a capillary-venous vascular malformation of the brain, skin and eye. Urine vascular biomarkers have been demonstrated to be abnormal in other vascular anomalies and to correlate with clinical severity and progression. The current study investigated the use of urinary matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) levels to non-invasively monitor the progression of SWS. Fifty-four urine samples were collected from patients seen at the Hunter Nelson Sturge-Weber Center at Kennedy Krieger Institute. Urine was analyzed for MMP-2, MMP-9, VEGF and bFGF levels and correlated with clinical outcome at the time of urine collection (n = 48) and 1 year following urine collection (n = 22). Analysis revealed that MMP-2 (p = 0.033) and MMP-9 (p = 0.010) were significantly more likely to be present in the urine of SWS subjects compared to controls and that bFGF was significantly more likely to be present at abnormal levels (p = 0.005). MMP-2 correlated with a more severe clinical score at the time of urine collection, while both MMP-2 and MMP-9 levels correlated with greater disease severity at time of collection. bFGF levels correlated with improved clinical score 1 year after urine collection. These results suggest that MMP-2 and MMP-9 levels may be useful in assessing SWS progression, as well as indicating which patients might benefit from more aggressive treatment, while bFGF levels may be useful in judging the efficacy of neurologic treatment in SWS.

KW - angiogenesis

KW - biological markers

KW - fibroblast growth factor

KW - remodeling

KW - risk assessment

KW - vascular endothelial growth factor-A

UR - http://www.scopus.com/inward/record.url?scp=84878354318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878354318&partnerID=8YFLogxK

U2 - 10.1177/1358863X13486312

DO - 10.1177/1358863X13486312

M3 - Article

C2 - 23720035

AN - SCOPUS:84878354318

VL - 18

SP - 122

EP - 128

JO - Vascular Medicine

JF - Vascular Medicine

SN - 1358-863X

IS - 3

ER -